Epizyme (NASDAQ:EPZM) Cut to Sell at ValuEngine

ValuEngine cut shares of Epizyme (NASDAQ:EPZM) from a hold rating to a sell rating in a report published on Thursday morning, ValuEngine reports.

A number of other equities research analysts have also recently issued reports on EPZM. BidaskClub raised shares of Epizyme from a sell rating to a hold rating in a research note on Wednesday. Cowen reissued a buy rating and set a $18.00 price target on shares of Epizyme in a research report on Thursday, October 31st. Zacks Investment Research cut shares of Epizyme from a hold rating to a sell rating and set a $11.00 price target for the company. in a research report on Monday, October 21st. Finally, HC Wainwright reissued a buy rating on shares of Epizyme in a research report on Thursday, October 31st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. Epizyme presently has a consensus rating of Buy and a consensus target price of $17.50.

Shares of NASDAQ EPZM traded up $0.78 during midday trading on Thursday, hitting $15.18. The company’s stock had a trading volume of 722,400 shares, compared to its average volume of 811,703. Epizyme has a one year low of $5.14 and a one year high of $16.59. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -8.83 and a beta of 2.40. The stock has a fifty day moving average price of $10.98 and a 200 day moving average price of $12.39. The company has a current ratio of 10.90, a quick ratio of 10.90 and a debt-to-equity ratio of 0.03.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.11. Epizyme had a negative net margin of 468.53% and a negative return on equity of 49.38%. The company had revenue of $5.72 million during the quarter, compared to analysts’ expectations of $5.50 million. On average, equities research analysts predict that Epizyme will post -1.89 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Epizyme by 29.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,564 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 1,262 shares during the period. Aperio Group LLC purchased a new stake in Epizyme during the 2nd quarter valued at $72,000. Rockefeller Capital Management L.P. bought a new position in Epizyme in the 2nd quarter worth $88,000. United Services Automobile Association bought a new position in Epizyme in the 2nd quarter worth $134,000. Finally, HarbourVest Partners LLC bought a new position in Epizyme in the 2nd quarter worth $177,000. 86.32% of the stock is owned by institutional investors and hedge funds.

Epizyme Company Profile

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

See Also: What is a capital gain?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit